What you should know:
1. AGA developed an approach providers should take when treating patients with suspected OIC. They issued guidance for four major treatments.
2. AGA recommends traditional laxatives as a first-line treatment citing a moderate quality of evidence.
3. AGA issued several recommendations concerning Peripherally Acting μ-Opioid Receptor Antagonists use, over no treatment:
For patients with laxative refractory OIC, AGA recommends naldemedine with a high quality of evidence and naloxegol with a moderate quality of evidence
The AGA also issued a conditional recommendation for using methylnaltrexone, citing low quality of evidence.
4. The AGA did not recommend the use of internal secretagogues, lubiprostone, or selective 5-HT agonist, prucalopride, citing evidence gaps for both treatments.
Read the full recommendation here.
More articles on gastroenterology:
How ASC price transparency relates to value-based care, M&A activity & more: 4 insights
ACS grants Children’s Minnesota surgery center certification — 3 insights
HCA announces $1B public offering that could be used for acquisitions — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
